Cue Biopharma, Inc. Payments of Debt Issuance Costs
Cue Biopharma, Inc. (CUE) reported Payments of Debt Issuance Costs of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2024-03-28
- Cue Biopharma, Inc. payments of debt issuance costs for the quarter ending 2023-12-31 was $0.00.
- Cue Biopharma, Inc. payments of debt issuance costs for the quarter ending 2023-09-30 was $0.00.
- Cue Biopharma, Inc. payments of debt issuance costs for the quarter ending 2023-06-30 was $0.00.
- Cue Biopharma, Inc. payments of debt issuance costs for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Cue Biopharma, Inc. payments of debt issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Cue Biopharma, Inc. payments of debt issuance costs for fiscal 2022 was $141.00K.
- Cue Biopharma, Inc. payments of debt issuance costs for fiscal 2021 was $0.00.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month | Payments of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $0.00 10-Q · filed 2023-11-03 | -$1.00K derived: sum of 4 quarters · filed 2024-03-28 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | -$1.00K derived: sum of 3 quarters · filed 2024-03-28 | -$1.00K derived: sum of 4 quarters · filed 2024-03-28 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | -$1.00K derived: sum of 2 quarters · filed 2024-03-28 | -$1.00K derived: sum of 3 quarters · filed 2024-03-28 | -$1.00K derived: sum of 4 quarters · filed 2024-03-28 | |
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$1.00K derived: sum of 2 quarters · filed 2024-03-28 | -$1.00K derived: sum of 3 quarters · filed 2024-03-28 | $141.00K 10-K · filed 2024-03-28 | $141.75K 10-K · filed 2023-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $142.00K 10-Q · filed 2023-11-03 | $142.00K derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $142.00K 10-Q · filed 2023-08-08 | $142.00K derived: sum of 3 quarters · filed 2023-08-08 | $142.00K derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $142.00K 10-Q · filed 2023-05-09 | $142.00K derived: sum of 2 quarters · filed 2023-05-09 | $142.00K derived: sum of 3 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $0.00 derived: sum of 2 quarters · filed 2023-03-21 | $0.00 10-K · filed 2023-03-21 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |